Pricing and reimbursement in U.S. pharmaceutical markets
Read Online
Share

Pricing and reimbursement in U.S. pharmaceutical markets by Ernst R. Berndt

  • 204 Want to read
  • ·
  • 29 Currently reading

Published by National Bureau of Economic Research in Cambridge, MA .
Written in English


Book details:

Edition Notes

StatementErnst R. Berndt, Joseph P. Newhouse
SeriesNBER working paper series -- working paper 16297, Working paper series (National Bureau of Economic Research : Online) -- working paper no. 16297.
ContributionsNewhouse, Joseph P., National Bureau of Economic Research
Classifications
LC ClassificationsHB1
The Physical Object
FormatElectronic resource
ID Numbers
Open LibraryOL24485122M
LC Control Number2010656248

Download Pricing and reimbursement in U.S. pharmaceutical markets

PDF EPUB FB2 MOBI RTF

Abstract In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical developments, and reasons why price discrimination is highly prevalent among branded pharmaceuticals. In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding. Abstract. In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical developments, and reasons why price discrimination is highly prevalent among branded by: Downloadable! In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical developments, and reasons why price discrimination is highly prevalent among branded pharmaceuticals.

Formerly known as PharmaStrat, our focus on pricing, market access, and reimbursement strategy provides our clients with exceptional decision-making resources. In an ever-evolving, increasingly competitive commercial landscape, achieving optimal market access is becoming ever more challenging for pharmaceutical clients. The following table shows the value of the top 10 pharmaceutical markets, measured by revenues in US dollars (USD) for The relative size of drug markets also reflects different healthcare practices and drug price controls in each country. In the United States, the FDA is responsible for approving new medications.   Book Description. Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value.   This survey article on pricing and reimbursement in US pharmaceutical markets first presents a theoretical framework for pricing of branded pharmaceuticals, initially without and then in the presence of prescription drug insurance, noting how the common designs of the insurance policy, co-insurance and co-payments, affect prices and utilization.

  DUBLIN, J /PRNewswire/ -- The "Pharmaceutical Pricing and Reimbursement: Global Markets" report has been added to 's offering.. During the first quarter of Pharmaceutical Pricing Policies in a Global Market Pharmaceutical policy making raises particular challenges in reconciling key objectives for health policy, such as ensuring affordable access to the latest effective drugs, with other important policy considerations, such as providing support to a valuable national industry. The Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers–our 11th edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique resource is your ultimate. (increasingly) the U.S., considerable discretion remains in the hands of prescribers. Prescribers also remain relatively accessible to drug companies when compared with other major markets. From a reimbursement perspective, pricing levels are typically second only to the U.S., with manufacturers facing little of the.